Cencora, Inc. $COR Shares Acquired by Diamant Asset Management Inc.
π Diamant Asset Management Inc. lifted its holdings in Cencora by 31,314% in Q1, buying 291,220 shares to own a total of 292,150 shares valued at $91.78 million.
π The company has a market cap of $55.83 billion, trading at a P/E ratio of 22.01 with a price-to-earnings-growth ratio of 1.59.
π° Cencora declared a $2.00 billion share buyback program authorized by the Board of Directors on May 21st to purchase up to 3.9% of its shares.
π΅ A quarterly dividend of $0.60 was paid on June 1st, representing an annualized yield of 0.8% with a payout ratio of 18.40%.
π Bank of America raised its price objective to $285.00 and maintained a neutral rating in a recent research report.
π UBS Group increased its target price to $412.00 and assigned a buy rating, while Morgan Stanley set a $342.00 price target.
π€ Director Lauren M. Tyler purchased 550 shares at an average cost of $270.23, increasing her direct ownership by 14.44% to 4,359 shares.
ποΈ Institutional ownership stands at 97.52%, with insider ownership at 0.38% as of the latest filings.
π The stock has a fifty-two week range between $244.82 and $377.54, currently trading above its 50-day moving average of $280.84.
π¬ Cencora operates as a global healthcare services company providing wholesale drug distribution, specialty pharmacy operations, and cold-chain logistics.
- Diamant Asset Management Inc. executed a massive 31,314% increase in its position, buying nearly one million dollars worth of shares to own $91.78 million of the stock.
- The Board of Directors approved a substantial $2.00 billion share buyback program, indicating strong confidence that the current stock price is undervalued relative to intrinsic value.
- Major institutional investors like Kemnay Advisory Services, Oakworth Capital, Elyxium Wealth, and Motiv8 Investments all acquired new stakes in the fourth quarter.
- Archer Investment Corp grew its position by 134.3% in the fourth quarter, adding 47 shares to its holdings.
- Analyst consensus is moderately bullish with twelve Buy ratings versus three Hold ratings, supported by a MarketBeat consensus target price of $367.75.
- UBS Group raised its price target to $412.00 and upgraded the sentiment to a buy rating, while Morgan Stanley set a specific target of $342.00.
- Weiss Ratings recently downgraded Cencora from a 'buy (b)' to a 'buy (b-)' rating, indicating a slight reduction in the strength of their positive outlook.
- Bank of America maintains a neutral rating with a price target of $285.00, suggesting that some analysts view the current valuation as fair rather than significantly undervalued.